Business News • PR NewsWire • Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

BRIDGEWATER, N.J. and TARRYTOWN, N.Y., June 4, 2017 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced positive preliminary results with investigational REGN2810, a checkpoint inhibitor targeting PD-1 (programmed death 1), in patients with advanced cutaneous...

View More : http://www.prnewswire.com/news-releases/sanofi-and-regeneron-present-positive-study-results-for-investigational-pd-1-ant...

Releted News by prnewswire

Acura Wins in the Motor City

Daratumumab Combination Therapy Improved Clinical Outcomes Regardless of Cytogenetic Risk for Previously-Treated Patients with Multiple Myeloma

Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting

ANA Systems elige a IBS Software como socio tecnológico estratégico

ANA Systems escolhe a IBS Software como parceira estratégica de tecnologia